Baiyang Pharmaceutical: The commercial drug Technetium [99mTc] pentetreotide injection has been approved for marketing.

Baiyang Pharmaceuticals announced that in April 2025, its subsidiary, Baiyang Zhihe, signed an agreement with Jiluntai to obtain the exclusive commercialization rights of Technetium [99mTc] Pectetide Injection. Recently, the National Medical Products Administration approved the drug for market launch. This drug is the first domestically developed Class 1 innovative nuclear medicine in China and the world's first broad-spectrum tumor imaging agent used for SPECT imaging. The approval for market launch will enrich the company's product portfolio, enhance competitiveness and profitability. However, sales may be affected by factors such as policies, markets, etc., leading to uncertainties.